Screening for Critical Congenital Heart Disease in Newborns

We have come a long way in our ability to treat critical congenital heart conditions, which affect about 3 of every 1000 live births and account for 30% of all infant fatalities in the United States annually.1 Prenatal sonograms can often identify structural heart disease; however, the sensitivity of congenital heart disease (CHD) detection is highly variable, depending on operator expertise, gestational age, fetal position, and the type of cardiac defect. As a result, prenatal sonography will miss some patients with critical CHD and is known to miss many newborns with simple CHD. Newborns who might benefit from early treatment can often be identified in their first days of life through pulse oximetry screening—a painless, readily available noninvasive examination that is easy to incorporate into newborn assessments. This noninvasive test measures the percentage of hemoglobin in the blood that is saturated with oxygen and pulse rate. The addition of pulse oximetry to fetal ultrasound and physical examination as a screening tool can reduce the chance of overlooking critical congenital heart disease (CCHD) in newborns.2Oxygen breathed in through the lungs attaches to the red blood cell protein hemoglobin. The newly oxygenated blood then circulates to the tissues. Arterial hemoglobin saturated with oxygen is bright red, and venous hemoglobin with less oxygen is darker. Pulse oximetry uses the principles of spectrophotometry and …